Immunotherapy -- creating antibodies to tumor markers, then activating the immune system to selectively kill cancer cells -- is the newest and most-hyped frontier of oncology.
NSCLC: Anti-PD-L1 immunotherapy breaks…
Immunotherapy -- creating antibodies to tumor markers, then activating the immune system to selectively kill cancer cells -- is the newest and most-hyped frontier of oncology.